Lynette Holzbaur Purchases 26,448 Shares of Organon & Co. (NYSE:OGN) Stock

Organon & Co. (NYSE:OGN) SVP Lynette Holzbaur purchased 26,448 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was bought at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the transaction, the senior vice president directly owned 52,851 shares of the company’s stock, valued at $705,560.85. This trade represents a 100.17% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Organon & Co. Stock Up 0.2%

Shares of NYSE OGN opened at $13.35 on Friday. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.23 and a current ratio of 1.97. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.44. The stock has a market capitalization of $3.50 billion, a P/E ratio of 14.35, a PEG ratio of 1.23 and a beta of 1.57. The stock’s fifty day moving average is $8.00 and its 200 day moving average is $7.82.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a return on equity of 99.95% and a net margin of 3.99%.The company had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter in the previous year, the business posted $1.02 EPS. The firm’s revenue for the quarter was down 3.5% on a year-over-year basis. Sell-side analysts forecast that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Investors of record on Monday, May 11th will be given a $0.02 dividend. The ex-dividend date is Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio (DPR) is presently 8.60%.

Institutional Trading of Organon & Co.

Several large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Organon & Co. by 2.7% during the fourth quarter. Vanguard Group Inc. now owns 36,916,382 shares of the company’s stock valued at $264,690,000 after purchasing an additional 987,979 shares in the last quarter. State Street Corp boosted its stake in shares of Organon & Co. by 2.8% during the fourth quarter. State Street Corp now owns 9,597,761 shares of the company’s stock valued at $68,816,000 after purchasing an additional 262,185 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Organon & Co. by 105.2% during the fourth quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock valued at $61,282,000 after purchasing an additional 4,394,814 shares in the last quarter. Private Management Group Inc. boosted its stake in shares of Organon & Co. by 38.3% during the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock valued at $31,169,000 after purchasing an additional 1,204,979 shares in the last quarter. Finally, UBS Group AG boosted its stake in shares of Organon & Co. by 55.2% during the fourth quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock valued at $30,795,000 after purchasing an additional 1,527,492 shares in the last quarter. 77.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 14th. Barclays raised their price objective on Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research note on Tuesday, February 24th. BNP Paribas Exane reaffirmed a “neutral” rating and issued a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a research note on Wednesday, April 29th. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and raised their price objective for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. Finally, Wall Street Zen lowered Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Four equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, Organon & Co. has an average rating of “Reduce” and an average target price of $11.40.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.